Singh Shawn
Known title: CHIEF EXECUTIVE OFFICERCIK: 0001412071
Singh Shawn's purchase track record
Singh Shawn has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/17/2022 | VTGN | $103K | -21.1% | +5.3% | -3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VTGN | ▲ Buy | Grant | 36,818 | $7K | 6/30/2026 | View on chart |
| VTGN | ▲ Buy | Grant | 7,541 | $13K | 6/30/2025 | View on chart |
| VTGN | ▲ Buy | Grant | 4,854 | $14K | 6/28/2024 | View on chart |
| VTGN | ▲ Buy | Grant | 167 | $287 | 12/29/2023 | View on chart |
| VTGN | ▲ Buy | Grant | 167 | $265 | 6/30/2023 | View on chart |
| VTGN | ▲ Buy | Grant | 5,000 | $438 | 12/30/2022 | View on chart |
| VTGN | ▲ Buy | Open Market | 600,000 | $103K | 8/17/2022 | View on chart |
| VTGN | ▲ Buy | Grant | 5,000 | $4K | 6/30/2022 | View on chart |
| VTGN | ▲ Buy | Option Exercise | 100,000 | $100K | 5/12/2022 | View on chart |
| VTGN | ▲ Buy | Grant | 3,623 | $6K | 12/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
VTGN linked to growing vasomotor symptoms market amid recent price dip
The vasomotor symptoms market is projected to expand through 2036 as adoption of hormonal and non‑hormonal therapies rises, a trend that aligns with VTGN’s focus on treatments for menopausal symptoms. At the same time, VTGN appeared on a recent list of falling stocks that traders are watching, indicating recent price weakness. These factors together provide context for the stock’s current market environment.
VTGN linked to growing vasomotor symptoms market amid recent price dip. The vasomotor symptoms market is projected to expand through 2036 as adoption of hormonal and non‑hormonal therapies rises, a trend that aligns with VTGN’s focus on treatments for menopausal symptoms. At the same time, VTGN appeared on a recent list of falling stocks that traders are watching, indicating recent price weakness. These factors together provide context for the stock’s current market environment.